Pfizer's 25-valent pneumococcal vaccine shows strong immune responses in Phase 2 infant trial

PFE•2026-10-24

Pfizer said its 25-valent pediatric pneumococcal vaccine candidate showed strong immune responses in a Phase 2 infant trial, with safety and tolerability comparable to Prevnar 20 and no vaccine-related serious adverse events identified.

Pfizer's 25-valent pneumococcal vaccine shows strong immune responses in Phase 2 infant trial

1. Phase 2 results

Related News

PubMatic CEO Rajeev K. Goel sells shares worth $863,237.4075

Zoom Communications director Herbert Raymond McMaster reports sale of $151,875 in common shares

Nasdaq halts trading pending news at 9:29 p.m.

Nasdaq trade halt: news pending at 09:29 p.m.

Masdar agrees to buy 550-plus MW Greek solar project from Lightsource bp